Skip to content
Review Open access

Hormonal target validation based on biochemical shifts in gender-affirming hormone therapy.

Sep 2026 · HORMONES · 0 citations · 33 references
Medicine

TL;DR

The innate sexual dimorphism of biochemical parameters might provide a framework for GAHT target validation and significantly different hormonal profiles can be seen in people depending on the biochemical shift experienced during GAHT.

Abstract

Background

Hormonal targets for gender-affirming hormone therapy (GAHT) remain largely unvalidated in gender-diverse individuals, with no clinical markers to assess dosing adequacy. We hypothesize that a biochemical shift towards the hormonal profile of the identified sex correlates with appropriate dosing.

Methods

A data-subset from the National Health and Nutrition Examination Survey (NHANES), comprising 5,433 assumed-cisgender individuals (47.2% male) aged < 52 years, was used to train and validate a random forest model to predict sex-registered-at-birth, incorporating platelet count, high-density lipoprotein cholesterol percentage, sex hormone-binding globulin (SHBG), creatinine, and hematocrit. The model was subsequently run in 174 transgender men (TM) and 135 transgender women (TW) from the European Network for the Investigation of Gender Incongruence (ENIGI) Ghent cohort. Blood samples were collected at 0, 3, 12, 18, 24, and 36 months after GAHT-initiation. Hormonal profiles were compared based on predicted sex-registered-at-birth.

Results

The model achieved 91% accuracy in NHANES, with baseline accuracy of 81.5% in ENIGI, declining to 10.7% at 36 months. Median estradiol (E2) concentrations in TW-predicted males-assigned-at-birth (59.0 ng/L, interquartile range, IQR: 45.3-73.3) were significantly lower (p < 0.0001) than in TW-predicted females-assigned-at-birth with a fully feminized biochemical signature (78.5 ng/L, IQR: 53.1-107.4). Difference in testosterone concentrations in TM-classified female-assigned-at-birth and predicted male-assigned-at-birth did not reach significance. Classification according to sex-at-birth seemed less likely to occur at higher E2 concentrations in TW.

Conclusion

The innate sexual dimorphism of biochemical parameters might provide a framework for GAHT target validation. Significantly different hormonal profiles can be seen in people depending on the biochemical shift experienced during GAHT.

Read PDF

Similar papers

Open access Oct 2026

Cardiometabolic Protein Profile Changes During Gender-Affirming Hormone Therapy: A Prospective Clinical Study.

T- and E2-based GAHT were associated with opposite directional changes in cardiometabolic protein profiles, and complement factor H and B, 3, 4b, 9, C-reactive protein, IGHA1, and afamin were higher in GAHT-ongoing TF individuals at baseline compared to GAHT-naïve TF individuals at 1 year.

Emilie Bukh Madsen, L. Christensen, Sara Ravn Bach et al. · 0 citations
Open access Sep 2026

Gender-affirming hormone therapy and liver diseases: a cohort study

The purpose of this study was to describe the incidence of liver-related outcomes, including liver disease and hepatic injury, in transgender and gender diverse (TGD) individuals receiving oestrogen-based or testosterone-based gender-affirming hormone therapy (GAHT). In this retrospective cohort study, we us...

Newsha Nikzad, Christina Dimopoulos-Verma, Seren M. Gedallovich et al. · 0 citations
Oct 2026

A-144 Assessment of hormone concentrations post-initiation of exogenous hormone therapies

Exogenous hormones are administered to supplement or replace deficient natural hormones and are used in a variety of indications, including hormone replacement therapy, gender-affirming care, and infertility treatment, among others. Therapeutic hormones for gender affirmation are generally assessed based on an in...

Maxwell L. Harsha, R. Bakshi, P. Akoijam et al. · 0 citations
Open access Oct 2026

Circulating 27-hydroxycholesterol, sex steroid hormones, and risk of mortality among postmenopausal females with breast cancer: The Multiethnic Cohort Study.

This seminal study of racially and ethnically diverse female breast cancer survivors found associations for pre-diagnostic 27HC, estrone, and SHBG with mortality and recommended that larger breast cancer cohorts be prioritize to confirm the findings and evaluate associations across important subgroups.

M. Sangaramoorthy, Debbie Goldberg, Adrian A. Franke et al. · 0 citations
Sep 2026

Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Treatment Recommendations.

In 2025, the US Food and Drug Administration (FDA) removed its prior class-wide boxed warnings for menopausal hormone therapy (MHT), paving the way for increased clinical use. Menopause accelerates cardiovascular risk independently of chronological aging, manifesting as a 7.5% increase in carotid-femoral pulse wave vel...

Ashwin A. Pillai, Aryan Mehta, Shea-Lee Godin et al. · 0 citations
Oct 2026

A Novel Approach to Characterization of the Female Hormone Profile: Feasibility and Research Application of Daily At-Home Urine Hormone Monitoring.

INTRODUCTION Accounting for and characterizing hormonal status and menstrual phase can add complication, time, and expense to studies, creating a barrier to conducting rigorous female-specific research. Recent advances in at-home urine hormone testing present a potentially feasible method for quantifying daily estrogen...

Katie R. Hirsch, Callie L. Unrein, Kaitlyn T. Ramey · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.